B-Cell CD20 Expression by Flow Cytometry, Quantitative
Also known as: CD20 QUANT
Use
This test is used to enumerate B cells in peripheral blood or monitor response to rituximab therapy in patients with autoimmune disorders. It is particularly useful in evaluating B-cell suppression following rituximab treatment. For assessing primary B-cell deficiency conditions, such as agammaglobulinemia or common variable immunodeficiency (CVID), a B Cell Subset Analysis is recommended.
Special Instructions
Not provided.
Limitations
The test's performance characteristics were determined by ARUP Laboratories but it has not been cleared or approved by the FDA. Specimen viability is crucial for accurate results; clotted, hemolyzed, or frozen specimens are unacceptable. Specimens received more than 72 hours post-collection may also yield unreliable results.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 8117-4 - CD19 Cells NFr Bld
- 8116-6 - CD19 Cells # Bld
- 94689-7 - CD20 Cells/Cells.CD19 NFr Bld
- 9558-8 - CD20 Cells # Bld
- 33193-4 - Viable cells NFr Bld
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
1 mL
Container
Green (sodium heparin). Also acceptable: lavender (EDTA) or pink (K2EDTA).
Storage Instructions
Specimen should be received within 72 hours of collection for optimal viable testing.
Causes for Rejection
Clotted, hemolyzed, or frozen specimens. Specimens received more than 72 hours from collection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant